- Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness.
- Peginterferon Lambda significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits by 50% (primary endpoint) and death by 60%.
- The Phase 3 TOGETHER study of Lambda is the second largest study to date of a COVID-19 therapeutic.
- Final analyses evaluated data from 1,936 patients, with 84% of patients receiving at least a single dose of any COVID-19 vaccine.
- 2.7% of patients (25 / 916) who received Lambda were hospitalized or had ER visits through Day 28, compared to 5.6% of patients who received placebo
- 42% risk reduction of COVID-19-related hospitalizations was observed when treated ≤7 days of symptom onset, and 60% when treated ≤3 days.
- One COVID-19-related death was reported in the Lambda group, and four in the placebo group.
- Eiger plans to discuss the results with FDA and submit a EUA as soon as possible.
- The Company licensed worldwide rights to Lambda from Bristol-Myers Squibb Co (NYSE:BMY).
- Price Action: EIGR shares are up 22.40% at $6.97 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Why Eiger BioPharmaceuticals Stock Is Jumping Today
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks